Augmentin Does NOT Provide Reliable Coverage Against Morganella morganii
No, Augmentin (amoxicillin-clavulanate) should not be used to treat Morganella morganii infections due to intrinsic resistance. This organism demonstrates universal or near-universal resistance to amoxicillin-clavulanate, making it an inappropriate choice regardless of infection severity or site.
Resistance Profile
The FDA label for Augmentin does not list Morganella morganii among organisms with established clinical efficacy, and the drug's spectrum explicitly excludes organisms producing certain β-lactamases that are not inactivated by clavulanic acid 1.
Clinical studies consistently demonstrate this resistance pattern:
- 95.9% resistance rate to amoxicillin-clavulanate in a Taiwanese cohort of 73 bacteremia patients 2
- 100% resistance (described as "ubiquitous" and "universal") in multiple studies examining M. morganii isolates 3, 2
- Uniform resistance documented in pediatric UTI cases, where all isolates were resistant to amoxicillin-clavulanate 4
Appropriate Antibiotic Choices
For Empiric Therapy (When M. morganii is Suspected):
Third-generation cephalosporins (ceftriaxone or cefotaxime) combined with an aminoglycoside are the preferred initial regimen:
- This combination is recommended for severe intra-abdominal infections where M. morganii may be encountered 5
- Successfully used in neonatal sepsis cases caused by M. morganii 6, 7
- Provides reliable coverage while awaiting susceptibility results
For Targeted Therapy (After Culture Confirmation):
Based on susceptibility patterns, the following agents show consistent activity:
- Amikacin: 100% susceptibility in pediatric UTI series 4
- Cefepime: 100% susceptibility 4
- Piperacillin-tazobactam: 98.2% susceptibility, with only 1.8% resistance 3
- Ceftazidime: 95.8% susceptibility 2
- Carbapenems (meropenem preferred): Most commonly used for severe infections, though 19.4% imipenem resistance has been reported 2, 8
Clinical Context
M. morganii bacteremia carries significant mortality risk (14.7-41% depending on severity) 3, 8, and inappropriate antibiotic therapy is the only independent risk factor for mortality (odds ratio 4.8) 2. This makes initial antibiotic selection critical.
Common Clinical Scenarios:
- Urinary tract infections (37-47.5% of cases): Use cefepime, amikacin, or piperacillin-tazobactam 3, 2
- Hepatobiliary infections (22-30.3% of cases): Third-generation cephalosporin plus metronidazole or piperacillin-tazobactam 5, 3
- Neonatal sepsis: Third-generation cephalosporin plus aminoglycoside 6, 7
Key Risk Factors for M. morganii Infection:
- Urological abnormalities (neurogenic bladder, catheter use) 4
- Diabetes mellitus and hypertension 3, 8
- Prior antibiotic exposure, particularly to ampicillin/amoxicillin 6
- Polymicrobial infections (30.3-45.2% of cases) 3, 2
Critical Pitfall
Never use Augmentin for suspected or confirmed M. morganii infections. The organism's intrinsic resistance mechanism is not overcome by clavulanic acid, and using this agent will result in treatment failure and potentially increased mortality 2.